Augmentin is Appropriate for Discharge in This Stable Patient
For a stable patient discharged home after laparoscopic appendectomy with perforation and the cultured polymicrobial flora you describe, amoxicillin-clavulanate (Augmentin) is an appropriate oral antibiotic choice. 1
Rationale Based on Guidelines and Microbiology
The 2010 SIS/IDSA guidelines for complicated intra-abdominal infections explicitly recommend amoxicillin-clavulanate as an acceptable oral agent for community-acquired infections of mild-to-moderate severity, including perforated appendicitis 1. Your patient's culture results—Citrobacter freundii, E. coli, E. faecalis, Streptococcus anginosus, and moderate Bacteroides fragilis—represent the typical polymicrobial flora of perforated appendicitis.
Coverage Analysis
Augmentin provides adequate coverage for this microbial profile:
- Gram-negative aerobes (E. coli, Citrobacter): Amoxicillin-clavulanate covers most community-acquired E. coli and many Citrobacter strains, though intrinsic resistance can occur with Citrobacter 2, 3, 4
- Anaerobes (Bacteroides fragilis): The clavulanate component provides reliable anti-anaerobic activity 1
- Gram-positive organisms (Streptococcus anginosus, Enterococcus faecalis): Both are typically susceptible to amoxicillin-clavulanate 5, 6, 7
Key Clinical Considerations
Duration: The guidelines support shortened courses (5-8 days total including IV therapy) for perforated appendicitis when patients are clinically stable 8, 9. Recent pediatric data demonstrates that shortened courses of amoxicillin-clavulanate (5-8 days total) have equivalent outcomes to prolonged courses (10-14 days) with no difference in readmission rates 8.
Dosing: Standard adult dosing is 875/125 mg twice daily 10. The patient should take it with food to minimize gastrointestinal intolerance and optimize clavulanate absorption 10.
When to Reconsider: If the patient develops fever, worsening abdominal pain, or signs of organ-space infection within 5-7 days, obtain repeat cultures and consider broader coverage. The presence of Citrobacter freundii warrants attention—while most strains are susceptible to amoxicillin-clavulanate, this organism can develop resistance during therapy through AmpC β-lactamase induction 3, 4. However, in a stable, discharged patient, this risk is acceptable with close outpatient follow-up.
Alternative Considerations
The guidelines also list ciprofloxacin plus metronidazole as an alternative oral regimen 1. However, recent pediatric data shows no difference in outcomes between amoxicillin-clavulanate and ciprofloxacin/metronidazole, and amoxicillin-clavulanate is better tolerated 8. Additionally, fluoroquinolone resistance in E. coli is increasing in many communities, and local susceptibility patterns should guide this choice if considered 1.
Common Pitfalls to Avoid
- Don't routinely add enterococcal coverage beyond what amoxicillin-clavulanate provides: The guidelines explicitly state empiric anti-enterococcal therapy beyond standard regimens is not necessary for community-acquired intra-abdominal infections 1
- Don't add antifungal therapy: Empiric antifungal coverage for Candida is not recommended in community-acquired perforated appendicitis 1
- Don't use ampicillin-sulbactam: This is explicitly not recommended due to high E. coli resistance rates 1
Monitoring Plan
Instruct the patient to complete the full antibiotic course and return immediately for fever >38.5°C, increasing abdominal pain, inability to tolerate oral intake, or other concerning symptoms. If clinical deterioration occurs, obtain repeat imaging (CT abdomen/pelvis) and blood cultures, and consider readmission for IV antibiotics targeting the cultured organisms with susceptibility-guided therapy 1.